Manenzhe Rendani I, Moodley Clinton, Abdulgader Shima M, Robberts F J Lourens, Zar Heather J, Nicol Mark P, Dube Felix S
Division of Medical Microbiology, Faculty of Health Science, University of Cape Town, Cape Town, South Africa.
National Health Laboratory Service, Groote Schuur Hospital, Cape Town, South Africa.
Front Microbiol. 2019 Mar 27;10:610. doi: 10.3389/fmicb.2019.00610. eCollection 2019.
Nasopharyngeal (NP) colonization by (pneumococcus) precedes the development of respiratory tract infection. Colonization by antimicrobial-resistant pneumococci, especially in infants, is a major public health concern. We longitudinally investigated antimicrobial-resistance amongst pneumococci colonizing the nasopharynx of South African infants immunized with the 13-valent pneumococcal conjugate vaccine (PCV13). NP swabs were collected every second week from birth through the first year of life from 137 infants. Pneumococci were identified and serotyped using conventional microbiological techniques, and their antibiotic susceptibility profiles determined by disk diffusion and -test. All infants were immunized with 3 doses of PCV13. 1520 pneumococci (760 non-repeat) isolates were recovered from 137 infants; including non-typeable ( = 99), PCV13 ( = 133) and non-PCV13 serotypes ( = 528). The prevalence of penicillin, erythromycin, and cotrimoxazole non-susceptibility was 19% (95% CI 17-22%) (3% fully resistant), 18% (95% CI 15-21%) (14% fully resistant), and 45% (95% CI 42-49%) (36% fully resistant), respectively. The predominant penicillin-non-susceptible serotypes included 19A, 19F, 15B/15C, 15A, and 21, while susceptible serotypes included 23A, 34, and 17A. Multidrug-resistance (MDR) was observed in 9% (95% CI 7-11%) of the isolates. PCV13 serotypes were more likely to be non-susceptible, compared to non-PCV13 serotypes, to penicillin (26% vs. 16%, = 0.007), erythromycin (23% vs. 15%, = 0.027) and cotrimoxazole (62% vs. 41%, < 0.001). Non-susceptibility to penicillin, erythromycin, and cotrimoxazole remained relatively constant through the first year of life ( test for trend: = 0.184, = 0.171, and = 0.572, respectively). Overall, penicillin or erythromycin-non-susceptible pneumococci were carried for a shorter duration than susceptible pneumococci [penicillin (mean days, 18 vs. 21, = 0.013) and erythromycin (mean days, 18 vs. 21, = 0.035)]. Within individual infants carrying the same serotype longitudinally, changes in antibiotic susceptibility were observed over time in 45% (61/137) of infants and these changes were predominantly for penicillin (76%, 79/104). Prevalence of NP carriage with antibiotic-non-susceptible pneumococci was relatively constant throughout the first year of life. PCV13 serotypes were more commonly non-susceptible to penicillin, erythromycin, and cotrimoxazole. Penicillin or erythromycin-non-susceptible pneumococci were carried for a shorter duration than penicillin or erythromycin-susceptible pneumococci.
肺炎链球菌在鼻咽部的定植先于呼吸道感染的发生。耐抗菌药物肺炎链球菌的定植,尤其是在婴儿中,是一个主要的公共卫生问题。我们纵向调查了接种13价肺炎球菌结合疫苗(PCV13)的南非婴儿鼻咽部定植的肺炎链球菌的耐药情况。从137名婴儿出生至1岁,每隔一周采集一次鼻咽拭子。使用传统微生物技术鉴定肺炎链球菌并进行血清分型,通过纸片扩散法和肉汤稀释法测定其抗生素敏感性谱。所有婴儿均接种3剂PCV13。从137名婴儿中分离出1520株肺炎链球菌(760株非重复菌株);包括不可分型(n = 99)、PCV13血清型(n = 133)和非PCV13血清型(n = 528)。青霉素、红霉素和复方新诺明不敏感的发生率分别为19%(95%CI 17 - 22%)(3%完全耐药)、18%(95%CI 15 - 21%)(14%完全耐药)和45%(95%CI 42 - 四十九%)(36%完全耐药)。主要的青霉素不敏感血清型包括19A、19F、15B/15C、15A和21,而敏感血清型包括23A、34和17A。9%(95%CI 7 - 11%)的分离株观察到多重耐药(MDR)。与非PCV13血清型相比,PCV13血清型对青霉素(26%对16%,P = 0.007)、红霉素(23%对15%,P = 0.027)和复方新诺明(62%对41%,P < 0.001)更易不敏感。在生命的第一年,对青霉素、红霉素和复方新诺明的不敏感性保持相对稳定(趋势检验:P分别为0.184、0.171和0.572)。总体而言,青霉素或红霉素不敏感的肺炎链球菌携带时间比敏感肺炎链球菌短[青霉素(平均天数,18对21,P = 0.013)和红霉素(平均天数,18对21,P = 0.035)]。在纵向携带相同血清型的个体婴儿中,45%(61/137)的婴儿随时间观察到抗生素敏感性变化,这些变化主要针对青霉素(76%,79/104)。抗生素不敏感肺炎链球菌的鼻咽部携带率在生命的第一年相对稳定。PCV13血清型对青霉素、红霉素和复方新诺明更常见不敏感。青霉素或红霉素不敏感的肺炎链球菌携带时间比青霉素或红霉素敏感的肺炎链球菌短。